Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Centene (CNC) Invests Nearly $8M to Build Texas Community Center
by Zacks Equity Research
Centene (CNC) collaborates with CHDI to establish a new community center in Texas, reflecting efforts to expand its Managed Care business across the state.
Why Is Shockwave Medical (SWAV) Down 8.3% Since Last Earnings Report?
by Zacks Equity Research
Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
Here's Why You Should Retain Hologic (HOLX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on the back of its continued strength in the Breast Health arm.
Catalent (CTLT) Expands Facility Capabilities in Shanghai
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Masimo (MASI) Announces Positive Study Results on PBM by SpHb
by Zacks Equity Research
Masimo's (MASI) SpHb is likely to enhance transfusion management and post-operative patient outcomes on patients.
Merit Medical (MMSI) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) slew of product launches.
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
Henry Schein's (HSIC) New Tie-Up to Improve Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) recent deal with VideaHealth is expected to aid dentists in proving greater transparency to patients, thus making better treatment recommendations and improving case acceptance.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
Boston Scientific's (BSX) New Buyout to Expand its Portfolio
by Zacks Equity Research
Boston Scientific's (BSX) latest buyout is expected to boost its Endoscopy business by adding Apollo Endosurgery's product portfolio, which includes devices used during ELS procedures.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.
Here's Why You Should Hold OPKO Health (OPK) Stock For Now
by Zacks Equity Research
OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.
Merit Medical (MMSI) Launches New Inflation Device basixALPHA
by Zacks Equity Research
Merit Medical (MMSI) launches basixALPHA inflation device in the United States for one-handed preparation and fast inflation with minimal exertion to streamline angioplasty procedures.
The Zacks Analyst Blog Highlights ShockWave Medical, iRadimed and Tactile Systems Technology
by Zacks Equity Research
ShockWave Medical, iRadimed and Tactile Systems Technology are part of the Zacks top Analyst Blog.
Factors That Make Elevance Health (ELV) a Lucrative Bet Now
by Zacks Equity Research
Elevance Health (ELV) continues to benefit from sustained top-line growth, higher membership in Government business and a sturdy financial position.
AmerisourceBergen (ABC) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Boston Scientific (BSX) Posts Positive Post-Market Study Data
by Zacks Equity Research
The latest PMCF study demonstrates that Boston Scientific's (BSX) ACURATE neo2 Aortic Valve System is expected to significantly improve patient outcomes.
3 Medical Instruments Stocks With Potential to Outperform
by Indrajit Bandyopadhyay
Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.
QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification
by Zacks Equity Research
QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.
Here's Why You Should Retain Stryker (SYK) Stock For Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.